Incyte welcomes Dr Ed Harrigan to its Board of Directors

– USA, DE –  Incyte Corporation (Nasdaq: INCY) today announced the appointment of Edmund P. Harrigan, M.D., as a new member of the Board of Directors, effective December 16, 2019.

“We are delighted to welcome Edmund to Incyte. His extensive leadership experience in a variety of important areas including Clinical, Regulatory and Business Development will be instrumental as we continue to develop and commercialize innovative medicines for serious unmet medical conditions,” said Hervé Hoppenot, CEO, Incyte. “We look forward to benefiting from his valuable experience and further strengthening Incyte’s leadership.”

About Dr Edmund Harrigan

Dr. Harrigan served in various senior roles at Pfizer, Inc., including Senior Vice President of Worldwide Safety and Regulatory from 2012 until his retirement in 2015. Dr. Harrigan’s previous executive leadership roles at Pfizer included Senior Vice President, Head of Worldwide Business Development; Senior Vice President, Head of Worldwide Regulatory Affairs and Quality Assurance; and Vice President, Head of Neuroscience and Ophthalmology. In addition, he has served in senior leadership positions at Karuna Pharmaceuticals, Inc., Sepracor Inc. and Neurogen Corporation. Prior to joining the pharmaceutical industry in 1990, Dr. Harrigan was a practicing neurologist for seven years.

“It is an exciting time to be joining Incyte as the company strives to advance clinical candidates from its diverse portfolio,” said Dr. Harrigan. “I look forward to working closely with the team to deliver on the company’s commitment to improving the lives of patients worldwide and building sustainable value for stakeholders.”

Dr. Harrigan earned his B.A. in Chemistry from St. Anselm College and M.D. from the University of Massachusetts.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.